With nearly 40 published peer-reviewed journal articles under its belt, Adherium is hoping that the latest clinical data which underlines the ability of the company’s Smartinhaler to improve outcomes for children with poorly controlled asthma should boost the pairing of digital technologies with drugs. Download the press release here Or visit Medtech Insight
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2016-11-19 21:41:412018-01-04 21:42:34New Data Gives Adherium Fuel To Accelerate Digital Tech Adoption in Drug Sector
Tuesday October 25, 2016 SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, today announced topline results from its Phase 1 trial to evaluate the safety and tolerability of AB-SA01, its proprietary investigational phage cocktail targeting Staphylococcus aureus (S. aureus) infections in patients suffering […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2016-10-25 21:42:462018-01-04 21:43:45AmpliPhi Biosciences Announces Favorable Topline Safety and Tolerability Results from Its Phase 1 Trial in Patients with Chronic Rhinosinusitis
Monday 24 October 2016. 24 October 2016: Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, is pleased to announce the start of a new clinical trial treating patients who have had a stroke or brain injury, with Robot-Assisted Physiotherapy with REX. The trial is being […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2016-10-24 21:44:152018-01-05 19:41:10REX Stroke and Brain Injury Clinical Trial in Australia
Sarah-Jane Tasker – The Australian October 13, 2016 BioScience Managers is a small step away from running a $150 million fund under the government’s Biomedical Translation Fund, a move it says will revitalise the biotech sector. Jeremy Curnock-Cook, the managing director of Melbourne-based BioScience Managers, said the translation fund was an important initiative as it […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2016-10-13 21:45:212018-01-04 21:46:05BioScience to lure big super – The Australian
Melbourne, Australia, 3 October, 2016 – Australia’s innovative healthcare and biomedical research sectors are set for a massive boost with the launch of a new venture capital fund. “This is a breakthrough moment for many earlier stage, unlisted companies,” said BioScience Managers’ managing director Jeremy Curnock Cook. “Access to funding is vital in turning ideas […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2016-10-03 21:46:102018-01-04 21:47:02BioScience Managers – New Bioscience Innovation Fund to Boost Australian Healthcare Startups
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2016-09-16 21:58:162018-01-04 21:59:14Avita Medical Appoints COO and VP of Sales and Marketing
Tuesday, September 13, 2016. Link here. NYSEMKT:APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced topline data from a Phase 1 trial to evaluate the safety and tolerability of AB-SA01, its proprietary investigational phage cocktail targeting Staphylococcus aureus (S. aureus) infections. […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2016-09-13 21:47:132018-01-04 21:47:58AmpliPhi Biosciences Announces Topline Results from Its Phase 1 Phage Therapy Trial Conducted in the United States
Monday, September 12, 2016. Link here. NYSEMKT:APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, announced the publication of data from a preclinical study conducted by its collaborators at the University of Leicester demonstrating the therapeutic and prophylactic efficacy of AmpliPhi’s proprietary phage […]
1 September 2016: Link here. Adherium Limited (ASX:ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, today announced Mr Thomas Lynch as Adherium’s new Chairman, and Dr Doug Wilson as Adherium’s executive Medical Director. Mr Lynch’s appointment follows a global search for a high profile Director with broad […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2016-09-01 21:49:182018-01-04 21:49:46ADR – Thomas Lynch appointed as new Adherium chairman
New Data Gives Adherium Fuel To Accelerate Digital Tech Adoption in Drug Sector
/in Portfolio CompaniesWith nearly 40 published peer-reviewed journal articles under its belt, Adherium is hoping that the latest clinical data which underlines the ability of the company’s Smartinhaler to improve outcomes for children with poorly controlled asthma should boost the pairing of digital technologies with drugs. Download the press release here Or visit Medtech Insight
AmpliPhi Biosciences Announces Favorable Topline Safety and Tolerability Results from Its Phase 1 Trial in Patients with Chronic Rhinosinusitis
/in Portfolio CompaniesTuesday October 25, 2016 SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics, today announced topline results from its Phase 1 trial to evaluate the safety and tolerability of AB-SA01, its proprietary investigational phage cocktail targeting Staphylococcus aureus (S. aureus) infections in patients suffering […]
REX Stroke and Brain Injury Clinical Trial in Australia
/in Portfolio Companies, Rex BionicsMonday 24 October 2016. 24 October 2016: Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, is pleased to announce the start of a new clinical trial treating patients who have had a stroke or brain injury, with Robot-Assisted Physiotherapy with REX. The trial is being […]
BioScience to lure big super – The Australian
/in BioSciences ManagersSarah-Jane Tasker – The Australian October 13, 2016 BioScience Managers is a small step away from running a $150 million fund under the government’s Biomedical Translation Fund, a move it says will revitalise the biotech sector. Jeremy Curnock-Cook, the managing director of Melbourne-based BioScience Managers, said the translation fund was an important initiative as it […]
BioScience Managers – New Bioscience Innovation Fund to Boost Australian Healthcare Startups
/in BioSciences ManagersMelbourne, Australia, 3 October, 2016 – Australia’s innovative healthcare and biomedical research sectors are set for a massive boost with the launch of a new venture capital fund. “This is a breakthrough moment for many earlier stage, unlisted companies,” said BioScience Managers’ managing director Jeremy Curnock Cook. “Access to funding is vital in turning ideas […]
Avita Medical Appoints COO and VP of Sales and Marketing
/in Portfolio CompaniesLink here.
AmpliPhi Biosciences Announces Topline Results from Its Phase 1 Phage Therapy Trial Conducted in the United States
/in Portfolio CompaniesTuesday, September 13, 2016. Link here. NYSEMKT:APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced topline data from a Phase 1 trial to evaluate the safety and tolerability of AB-SA01, its proprietary investigational phage cocktail targeting Staphylococcus aureus (S. aureus) infections. […]
AmpliPhi Biosciences’ Bacteriophage Cocktail Shown to Prevent C. difficile Biofilm Formation and Reduce Colonization
/in Portfolio CompaniesMonday, September 12, 2016. Link here. NYSEMKT:APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, announced the publication of data from a preclinical study conducted by its collaborators at the University of Leicester demonstrating the therapeutic and prophylactic efficacy of AmpliPhi’s proprietary phage […]
Avita Medical’s Regenerative Skin Technology significantly reduces burn scars and healing time
/in Portfolio CompaniesNorthridge, CA, Perth, Australia and London, United Kingdom – 2 September 2016 Link here.
ADR – Thomas Lynch appointed as new Adherium chairman
/in Portfolio Companies1 September 2016: Link here. Adherium Limited (ASX:ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, today announced Mr Thomas Lynch as Adherium’s new Chairman, and Dr Doug Wilson as Adherium’s executive Medical Director. Mr Lynch’s appointment follows a global search for a high profile Director with broad […]